RESEARCH THESIS: TO COMPARATIVELY EVALUATE SALE TRENDS OF SITAGLIPTIN AND DAPAGLIFLOZIN IN KALAMB AND YAVATMAL

The global rise in Type 2 Diabetes Mellitus (T2DM) has significantly increased the demand for effective oral hypoglycemic agents. Among the newer classes of antidiabetic drugs, Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, have gained substantial market share due to their efficacy and safety profiles. This study presents a comparative sales survey to evaluate the market performance, prescription patterns, and consumer acceptance of Sitagliptin and Dapagliflozin. Data were collected through structured questionnaires distributed among pharmacists, physicians, and medical representatives, along with retail sales data from selected pharmacies. Parameters such as monthly sales volume, cost-effectiveness, patient adherence, brand availability, and physician preference were analysed. The results indicate a notable increase in the sales of Dapagliflozin, primarily due to its additional benefits, including cardiovascular protection, weight loss, and renal benefits. Conversely, Sitagliptin continues to show consistent sales owing to its well-established safety profile, minimal risk of hypoglycaemia, and long-term clinical use. The study concludes that while Sitagliptin maintains a stable market position, Dapagliflozin is emerging as a preferred choice in recent years. Market growth is influenced by evolving clinical guidelines, patient awareness, and pharmaceutical marketing strategies. These findings provide valuable insights for healthcare providers and pharmaceutical companies in decision-making and strategic planning.